

Postdoctoral position in cellular and molecular biology of reprogramming

The candidate will integrate a dynamic and stimulating environment at the cancer research center of Lyon (CRCL) in the team of Fabrice Lavial, and will take advantage of the core facilities on site (microscopy, flow cytometry, single-cell, bioinformatics, organoids, tumor models) to develop his/her own project. The [“reprogramming, stem cells and oncogenesis”](#) team, composed of 12 members, dissects how cellular identity and plasticity are regulated during early development, pluripotent reprogramming and oncogenic transformation.

Mission:

The candidate will explore the molecular mechanisms that regulate reprogramming *in vivo* in mice and *ex vivo* in organoids. She/he will contribute to decipher the reprogramming routes but also to set up a Crispr/Cas9 KO-mediated KO screening of epigenetic regulators.

Activities:

- *In vivo* experiments in genetically engineered mice
- Cell culture (2D, 3D)
- Histology on tissue cryosections
- Molecular biology
- Cytometry
- Crispr/Cas9 KO-mediated screening
- Analysis and interpretation of the data
- “Veille” scientifique

Skills:

- Expertise in stem cell or adult/pediatric cancers
- Autonomy and ability to drive the project
- Planning, organization and relational sense
- Excellent communication and writing skills
- Fluency in English

Contract start date:

Flexible, between spring 2024 and spring 2025.

Contract duration:

24 months, renewable. The funding is coming from the [Fondation Bettencourt Schueller](#) and its [Impulscience](#) program. Candidates are expected to apply for independent fundings. Assistance will be provided during the application process. Please submit CV, cover letter, concise description of past achievements and academic goals, and contact details for 2-3 referees. Candidates are encouraged to apply as soon as possible.

Contact: Fabrice.lavial@lyon.unicancer.fr

Recent publications of the lab:

Nature Cell Biology 2020, Nature Cell Biology 2022, Trends in Cell Biology 2023, Nature Communications 2023.

